Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
May 22, 2013
Dividend Growth Gem Medtronic Is a Cash Cow
Full-year free cash flow of $4.4 billion confirms that Medtronic is a cash cow. Feb 19, 2013
Dividend Growth Portfolio Holding Medtronic Posts Solid Third Quarter
Medtronic’s third quarter was solid. Free cash flow remains terrific. Jan 22, 2013
Johnson & Johnson’s Long-term Tailwinds Are Intact
Johnson & Johnson reported solid fourth-quarter results. The firm's long-term tailwinds remain intact. Dec 1, 2012
A Dual Focus on Valuation and Yield Is the Best Way to Combat Changes in Future Dividend Tax Rates
We think a dual focus on both valuation and high-yielders remains the best way to achieve portfolio income growth, while reducing the risk of permanent loss of capital from valuation missteps and exogenous events, namely potential changes in the dividend tax rate. Aug 22, 2012
Dividend Growth Gem Medtronic Posts a Decent First Quarter
Medical heart-rhythm device maker Medtronic posted solid first-quarter results. The company remains an attractive dividend growth idea. Jul 19, 2012
Our Outlook for the Market
President of Equity Research & ETF Analysis, Brian Nelson offers insight into Valuentum's outlook for the market. Jun 22, 2012
Dividend Growth Favorite Medtronic Raises Dividend 7%
Medical device-maker Medtronic (MDT) announced that it will increase its quarterly dividend 7% to $0.26 per share. This translates to a pay out of $1.04 per year, or an annual yield of 2.8% at current levels. Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry. May 22, 2012
Medtronic Gaining Share in the US Drug-Eluting Stent Market
Medtronic posted strong fiscal fourth-quarter results and offered a solid outlook for its fiscal 2013. We're big fans of the medical device maker's dividend-growth profile and expect the company to continue to return cash to shareholders.
Tandem Diabetes Care: An Emerging Leader in Diabetes Technology
Image Source: Tandem Investor PresentationOver the past year or so, Tandem Diabetes Care has gone from jockeying for position in the domestic insulin pump market to a global leader in diabetes care technology. Significant growth catalysts remain in place, and the company expects to soon begin realizing meaningful efficiencies of scale as robust top-line growth continues. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
